Kevin Charles Gorman sold $13.4M of Neurocrine Biosciences (NBIX)

Executed Aug 7 2025, disclosed Aug 11 2025, 4 days later.

Value, as filed

$13.4M

106,322 sh × $126.41

Executed

Aug 7 2025

the trade date, as filed

Disclosed

Aug 11 2025

4 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

KG Kevin Charles Gorman Director profile →

Kevin Charles Gorman (Director) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Neurocrine Biosciences, Inc. (NBIX). The largest single filing was $37.8M of NBIX (245,088 sh × $154.33, as filed), executed May 19.

The name

NBIX Neurocrine Biosciences, Inc. NBIX · Healthcare · 59 filings in 24 months ticker →

Healthcare · Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunolog…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Kevin Charles Gorman in NBIX

NBIXSALE Neurocrine Biosciences, Inc. $37.8M
245,088 sh × $154.33
Exec May 19
Filed May 21 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $1.2M
9,613 sh × $120.38
Exec May 27 2025
Filed May 29 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $682K
5,844 sh across 2 lots
Exec Feb 13 2025
Filed Feb 14 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $269K
2,274 sh × $118.37
Exec Feb 10 2025
Filed Feb 12 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $414K
2,707 sh × $152.92
Exec Jan 31 2025
Filed Feb 4 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. $21.8M
146,105 sh × $149.46
Exec Jan 27 2025
Filed Jan 29 2025 · 5:30 PM ET